Video

Dr. Jonasch on the Promise of Belzutifan in Metastatic RCC

Eric Jonasch, MD, discusses the promise of the hypoxia inducible factor-2 alpha inhibitor belzutifan in metastatic renal cell carcinoma.

Video Player is loading.
Current Time 0:00
Duration 1:18
Loaded: 0%
Stream Type LIVE
Remaining Time 1:18
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
  • en (Main), selected

Eric Jonasch, MD, professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the promise of the hypoxia inducible factor-2 alpha (HIF-2α) inhibitor belzutifan (Welireg) in metastatic renal cell carcinoma (RCC).

Data from the phase 1 LITESPARK-001 trial (NCT02974738) showed that the HIF-2α inhibitor belzutifan (Welireg) demonstrated an objective response rate (ORR) of 25% and a median progression-free survival (PFS) of 14.5 months in patients with metastatic RCC, Jonasch explains.

Additional studies investigating belzutifan in combination with cabozantinib (Cabometyx) in the frontline and second-line settings have also displayed benefits for patients with metastatic RCC, Jonasch continues. In cohort 1 of the phase 2 LITESPARK-003 trial (NCT03634540), patients with treatment-naïve metastatic RCC who received belzutifan plus cabozantinib experienced an ORR of 57% and a median PFS of 30.3 months, Jonasch concludes.